Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results

Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-integrated part of the clinical care of multiple sclerosis (MS) in several European countries. ADA data generated in Europe during the more than 10 years of ADA monitoring in MS patients treated with interferon beta (...

Descripción completa

Detalles Bibliográficos
Autores principales: Link, Jenny, Ramanujam, Ryan, Auer, Michael, Ryner, Malin, Hässler, Signe, Bachelet, Delphine, Mbogning, Cyprien, Warnke, Clemens, Buck, Dorothea, Hyldgaard Jensen, Poul Erik, Sievers, Claudia, Ingenhoven, Kathleen, Fissolo, Nicolas, Lindberg, Raija, Grummel, Verena, Donnellan, Naoimh, Comabella, Manuel, Montalban, Xavier, Kieseier, Bernd, Soelberg Sørensen, Per, Hartung, Hans-Peter, Derfuss, Tobias, Lawton, Andy, Sikkema, Dan, Pallardy, Marc, Hemmer, Bernhard, Deisenhammer, Florian, Broët, Philippe, Dönnes, Pierre, Davidson, Julie, Fogdell-Hahn, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295710/
https://www.ncbi.nlm.nih.gov/pubmed/28170401
http://dx.doi.org/10.1371/journal.pone.0170395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295710/
https://www.ncbi.nlm.nih.gov/pubmed/28170401
http://dx.doi.org/10.1371/journal.pone.0170395

Ejemplares similares